Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck
| Autor: | Nikhil G. Rao, Tawee Tanvetyanon, Andy Trotti, Judith C. McCaffrey, Tapan A. Padhya, Ronald C. DeConti, Julie A. Kish |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry medicine.medical_treatment Hazard ratio Head and neck cancer Retrospective cohort study medicine.disease Radiation therapy stomatognathic diseases Otorhinolaryngology Internal medicine medicine Adjuvant therapy Stage (cooking) Skin cancer business Adjuvant |
| Zdroj: | Head & Neck. 37:840-845 |
| ISSN: | 1043-3074 |
| Popis: | Background Despite resection followed by adjuvant radiotherapy, high-risk cutaneous squamous cell carcinomas of the head and neck region (SCCHN) often recur. Because adjuvant concurrent chemoradiation reduces recurrence among high-risk mucosal SCCHN, we sought to understand its efficacy among high-risk cutaneous SCCHN. Methods We conducted a retrospective cohort study of patients with cutaneous SCCHN who underwent adjuvant radiation or concurrent chemoradiation. Patients must have had stage III/IV with high-risk features, including metastatic involvement of ≥2 lymph nodes, positive margins, or extracapsular invasion. Results There were 61 patients: 27 (44%) received adjuvant radiation and 34 (56%) received adjuvant chemoradiation. The median recurrence-free survivals were 15.4 and 40.3 months, respectively. Adjuvant chemoradiation significantly decreased the risk of recurrence or death in a multivariable analysis: hazard ratio (HR) 0.31 (p = .01). However, a difference in overall survival was not found. Conclusion For high-risk cutaneous SCCHN, adjuvant chemoradiation was associated with a better recurrence-free survival than adjuvant radiation alone. © 2014 Wiley Periodicals, Inc. Head Neck 37: 840–845, 2015 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text